Aktis Oncology, Inc.

AKTS · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $1.0B · 79 employees
8
SEC Filings
$21.88
Close 2026-09-18
79
Employees

Business Summary

Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals using a proprietary miniprotein radioconjugate platform. Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4 and is in Phase 1b trials for locally advanced or metastatic urothelial cancer and other solid tumors. The company focuses on alpha-emitting radioisotopes, end-to-end supply chain development, and expanding radiopharmaceutical use beyond traditional nuclear medicine settings.

Latest Stock Quote

AKTS 2026-09-18 $21.88 O:$22.86 H:$23.085 L:$21.875 Vol:2.7M VWAP:$22.0369
origin leaf: null

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001193125-26-131748EDGAR147K words

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-08-132026-06-300001193125-26-349144EDGAR20K words

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-08-130001193125-26-349133EDGAR2K words
2026-03-300001193125-26-132524EDGAR1K words
2026-01-120001193125-26-010354EDGAR15K words

8 total filings indexed. 3 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACIU — AC Immune SA ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA

Tags

oncology radiopharmaceuticals urothelial-cancer breast-cancer lung-cancer targeted-cancer-therapy cgmp-(current-good-manufacturing-practice) dota-chelation-chemistry ind-(investigational-new-drug)-regulatory-framework section-21-mrsa-(medicines-and-related-substances-act)

Company Identity

CIK0002035832
TickerAKTS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
Websitehttps://www.aktisoncology.com
Listed2026-01-09

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 42c86442fd4b948806e606308ebb8b2dff40eb7f77357926cbd360e9d91d4c2e
parent: c1de93f10929a94b9ccada462940acaeda9656704ae1463beaa7f3e0a98d26c5
content hash: a561ffe387a9db1f0e53d71eaccfe22d1f9ee0077d6263d509286663107ba4b1
signed: 2026-09-30T19:00:12.565Z
sources: 2 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up AKTS using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on AKTS, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/AKTS (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.